WASHINGTON, D.C. and NORWELL, Mass. — Three of the nation’s most prominent federal health leaders are set to take center stage at the upcoming 2026 NORD® Rare Diseases and Orphan Products Breakthrough Summit®, scheduled for October 25–27 in Washington, D.C. The annual event, recognized as the nation’s largest and longest-standing gathering dedicated to rare diseases, will convene more than 900 rare disease stakeholders representing patient advocacy, private industry, public policy, advanced science, and clinical medicine.
Acting Commissioner of Food and Drugs Kyle Diamantas, J.D., National Institutes of Health (NIH) Director Jay Bhattacharya, M.D., Ph.D., and Stephanie E. Haridopolos, M.D., DABFM, Director of National Health Communications for the Office of the Surgeon General and Principal Deputy Assistant Secretary for Health Policy, will address the massive assembly. Their participation highlights a crucial moment for the rare disease community as leaders from across government, research, and patient advocacy sectors collaborate to tackle pressing challenges and scale innovative solutions for the more than 30 million children and adults in the United States living with rare conditions.
Pam Gavin, Chief Executive Officer of NORD, emphasized the significance of having high-ranking federal officials actively engage with the community at this critical juncture.
"Rare disease is at a pivotal moment, and it is important for our community to hear directly from the federal leaders helping shape what comes next," said Gavin. "Their presence at the NORD Breakthrough Summit reflects our longstanding partnership and continued collaboration with the FDA, NIH and Office of the Surgeon General, as well as their commitment to the rare disease community. The work they lead across research, regulation and public health is critical to building on today’s scientific breakthroughs and translating that progress into meaningful advances for people living with rare diseases."
The participation of these key federal figures underscores a shared national priority: bridging the gap between cutting-edge scientific discovery and practical, accessible patient care. With roughly one in ten Americans affected by a rare disease, the sheer scope of the challenge requires unprecedented cooperation across federal regulatory agencies, independent research institutions, the pharmaceutical and biotechnology sectors, and patient-led advocacy organizations.
FDA Acting Commissioner Kyle Diamantas to Outline Regulatory Pathways
As Acting Commissioner of Food and Drugs, Kyle Diamantas leads the federal agency tasked with the critical responsibility of regulating drugs, biologics, medical devices, and diagnostic tools. These products form the backbone of modern medical care and are especially vital for developing treatments where no prior standard of care exists.
Demonstrating an early commitment to collaborative dialogue, Diamantas organized a roundtable with rare disease advocates, including representatives from NORD, shortly after stepping into his current role. The objective of that engagement was to listen directly to patients, families, and advocates regarding how the U.S. Food and Drug Administration can better navigate the unique regulatory hurdles inherent in rare disease therapeutic development.
His keynote address and participation at the 16th annual summit will offer attendees direct insight into the regulatory priorities, modern approval pathways, and administrative frameworks that will shape the future of rare disease innovation. Navigating the path from bench science to commercial availability remains one of the most significant barriers for orphan product developers, making the FDA leadership’s perspective vital for industry stakeholders and patient advocates alike.
NIH Director Jay Bhattacharya to Discuss Biomedical Research and Emerging Technologies
At the helm of the National Institutes of Health, Dr. Jay Bhattacharya oversees the nation’s premier biomedical research enterprise. The NIH serves as the foundational engine driving the scientific discoveries that eventually underpin new diagnostic tools, targeted treatments, and potential cures for complex genetic and acquired rare conditions.
Under Dr. Bhattacharya’s leadership, the research community is increasingly leaning into advanced computational methodologies and public-private partnerships. The integration of artificial intelligence and machine learning models into electronic health record data analysis is opening new avenues for identifying patient populations, tracking disease progression, and designing more efficient clinical trials.
Furthermore, the NIH is heavily invested in public-private initiatives designed to build standardized platforms for gene-targeted therapies. These standardized platforms aim to streamline development processes, thereby accelerating the delivery of life-changing gene therapies to children and adults suffering from rare disorders. Dr. Bhattacharya’s address will provide critical clarity on how various NIH institutes and centers are aligning their strategic objectives to support individuals living with one or more rare conditions.

Dr. Stephanie E. Haridopolos Honored for Newborn Screening Leadership
Dr. Stephanie E. Haridopolos brings a profound, longstanding dedication to rare disease advocacy into her dual roles as Director of National Health Communications for the Office of the Surgeon General and Principal Deputy Assistant Secretary for Health Policy. At the upcoming summit, Dr. Haridopolos will address attendees regarding her extensive work in advancing newborn screening initiatives and will be honored with NORD’s 2026 Rare Impact Award® in the category of Policy Changemaker.
Her recognition stems from monumental policy shifts achieved in recent years. In 2025, two serious rare conditions—Duchenne muscular dystrophy and metachromatic leukodystrophy—were officially added to the Recommended Uniform Screening Panel (RUSP). Dr. Haridopolos played a key leadership role in advancing this crucial inclusion, which ensures that newborns across the country can be tested for these conditions shortly after birth.
In addition to expanding the RUSP, Dr. Haridopolos has been a vital contributor to the Newborn Screening Working Group. This collaborative body is working to systematize operational protocols for the RUSP, ultimately expanding opportunities for earlier diagnosis and timely clinical intervention for children born with rare diseases, which can drastically alter long-term health outcomes.
Comprehensive Federal Representation and Industry Collaboration
Beyond the high-profile keynote speakers, the 2026 Breakthrough Summit will feature a comprehensive federal regulatory panel. This panel will include senior representatives from several key components of the FDA, including the Center for Drug Evaluation and Research (CDER), the Center for Biologics Evaluation and Research (CBER), the Center for Devices and Radiological Health (CDRH), and the agency’s dedicated Rare Disease Innovation Hub.
Bringing together leaders from these distinct centers ensures a holistic exploration of the regulatory landscape, touching upon small molecule drugs, biological products, advanced cell and gene therapies, medical devices, and sophisticated diagnostic tools.
For the more than 30 million Americans facing the daily realities of a rare disease diagnosis, the timing of these discussions is critical. Rapid advancements in genomics, molecular biology, and digital health are creating unprecedented possibilities for earlier detection and targeted treatment. However, these same emerging technologies place immense pressure on the nation’s traditional research, regulatory, and healthcare delivery systems to modernize and adapt at an equal pace.
The active presence of federal health leaders at the summit serves as a powerful testament to the necessity of cross-sector collaboration. By uniting government officials, independent researchers, clinicians, biopharmaceutical executives, and the patient community, the event aims to foster an environment where scientific progress can be translated rapidly into faster diagnoses, broader treatment access, and significantly improved health outcomes for the one in ten Americans impacted by a rare disease.
Now celebrating its 16th year, the NORD Breakthrough Summit continues to serve as the nation’s premier forum for addressing the multifaceted issues surrounding rare diseases and orphan products. The complete agenda, speaker lineup, and registration details for the October event are available online through the official summit portal at NORDSummit.org.
About the National Organization for Rare Disorders (NORD®)
Established in 1983, the National Organization for Rare Disorders (NORD®) operates as an independent, nonpartisan 501(c)(3) nonprofit organization dedicated to driving improvements in the health and overall quality of life for the more than 30 million Americans affected by rare diseases. Working in close collaboration with over 350 disease-specific member patient organizations and a comprehensive Rare Disease Centers of Excellence network spanning more than 170 premier medical research institutions and children’s hospitals nationwide, NORD spearheads initiatives in clinical care, groundbreaking research, public education, and aggressive federal and state advocacy. Additional information regarding the organization’s programs and mission can be found at rarediseases.org.
Media Contact:
Cheryl Herbert
Vice President, Marketing & Communications
National Organization for Rare Disorders (NORD)
[email protected] / 719-330-4053
